Prospectus Supplement Adds New Selling Stockholders for 400,000 Warrant Shares Resale
Summary
Protara Therapeutics filed a prospectus supplement to include new selling stockholders, Warberg Special Situations Fund LP and Warberg WF XIII LP, who may resell up to 400,000 shares underlying warrants.
Key Events
-
New Selling Stockholders Added
Warberg Special Situations Fund LP and Warberg WF XIII LP have been added as selling stockholders via an assignment of common warrants.
-
Potential Resale of 400,000 Shares
These new selling stockholders may resell up to 400,000 shares of common stock underlying warrants.
-
No Proceeds to Company
The company will not receive any proceeds from the sale of shares by these selling stockholders.
-
Follows Recent Institutional Selling
This update comes amidst a series of Form 144 filings from other institutional investors (Baker Brothers) indicating intent to sell shares.
Analysis
This 424B7 filing updates a previous resale prospectus, adding Warberg Special Situations Fund LP and Warberg WF XIII LP as new selling stockholders. These entities received an assignment of common warrants exercisable for a total of 400,000 shares. While the company receives no proceeds from these potential sales, the addition of new institutional investors intending to resell shares contributes to an overhang on the stock. This follows a series of Form 144 filings from other institutional investors (Baker Brothers) in recent days, indicating a broader trend of institutional selling pressure.
At the time of this filing, TARA was trading at $5.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $304.6M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.